


Press Release

IOL Chemicals and Pharmaceuticals Ltd strong performance in FY20

Dated: 12.06.2020


Place: Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals today posted remarkable operational and financial performance for the quarter and year ended 31st March 2020.




Year ended March 2020 v/s Year ended March 2019

- Total Income increased by 13% to ₹ 1910.49 crore from ₹ 1695.70 crore.
- EBIDTA increased by 40% to ₹ 589.90 crore from ₹ 420.02 crore.
- PAT increased by 53% to ₹ 361.29 crore from ₹ 236.70 crore.
- EPS increased by 51% to ₹ 63.51 from ₹ 42.11




Quarter ended March 2020 v/s Quarter ended March 2019

- Total Income increased by 5% to ₹ 446.81 crore from ₹ 424.49 crore.
- EBIDTA decreased by 11% to ₹ 142.20 crore from ₹ 159.34 crore.
- PAT decreased by 11% to ₹ 90.03 crore from ₹ 101.65 crore.
- EPS decreased by 8% to ₹ 15.87 from ₹ 17.22



Quarter ended March 2020 v/s Quarter ended December 2019

- Total Income decreased by 13% to ₹ 446.81 crore from ₹ 515.21 crore.
- EBIDTA decreased by 13% to ₹ 142.20 crore from ₹ 163.46 crore.
- PAT decreased by 8% to ₹ 90.26 crore from ₹ 98.01 crore.
- EPS decreased by 8% to ₹ 15.87 from ₹ 17.22.



Speaking on improved operational and financial performance of the Company “during the financial year 2019-20”, Mr Vijay Garg, Joint Managing Director, apprised that the Company has become debt free by pre-paying its outstanding term loan. There is no term loan outstanding as on 31st March, 2020. He, further, added that the Company has paid Interim Dividend of ₹ 3/- per Share for the “Financial Year 2019-20”, in March 2020”.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.